Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis

• by Jonathan I. Silverberg, Eric L. Simpson, Saleem A. Farooqui, Gary Chan, Pinaki Biswas, Erman Güler

• May 20, 2026

Is Kaposi’s sarcoma the end of the OX40/OX40L axis in atopic dermatitis?

• by Shahram Salek-Ardakani

• June 2, 2026

Smartwatch May Track AD Status in Children

Wearable-derived scratching measures align with disease activity and short-term treatment response in pediatric patients with atopic dermatitis.

• by Andrea Surnit

• May 5, 2026

• 3 min

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial

• by Melinda Gooderham, Christopher G. Bunick, JiaDe Yu, Douglas Maslin, Shannon K. R. Schneider, Marie Louise Østerdal, Anders Søhoel, Daniel Elenius Madsen, Lawrence F. Eichenfield

• May 17, 2026